Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study
Sean H. Lim(University Hospital Southampton NHS Foundation Trust), David Goldblatt(Great Ormond Street Hospital), D. Lifson Jeffrey(NIHR CRUK Experimental Cancer Medicine Centre), Peter Johnson(Cancer Research UK), Karen Long(Southampton General Hospital), Anna Bowzyk Al-Naeeb(Bedford Hospital), Celine Galloway(Cancer Research UK), Diana Ayres(University Hospital Southampton NHS Foundation Trust), Ann O’Callaghan(Portsmouth Hospitals NHS Trust), Matthew J. Ahearne(University of Leicester), Carina Mundy(Cancer Research UK), J. Falconer(University Hospital Southampton NHS Foundation Trust), Marina Johnson, Victoria Willimott(Norfolk and Norwich University Hospitals NHS Foundation Trust), Nicola Campbell(Cancer Research UK), Benjamin Ward(Cancer Research UK), Andrew Bates, Helen G. Coleman(Queen's University Belfast), Andrew Davies(University Hospital Southampton NHS Foundation Trust), James Batchelor, Kate Rolfvondenbaumen(Cancer Research UK), Robert Lown(Anthony Nolan), Saul N. Faust(University Hospital Southampton NHS Foundation Trust), Tobias Menne(Newcastle upon Tyne Hospitals NHS Foundation Trust), Christopher P. Fox(University of Nottingham), Anna H. Turaj(Cancer Research UK), Thomas A. Wynn(National Institute of Allergy and Infectious Diseases), Beth Stuart(Queen Mary University of London), Adam G. Kelly(University of Southern California), Graham P. Collins(Churchill Hospital), Débora Joseph‐Pietras(Cancer Research UK), Oliver Brake(University Hospital Southampton NHS Foundation Trust), Adam Coleman(Cancer Research UK), Lisa A. Robinson(County Hospital)
Cited by 91
Related Papers
QuPath: Open source software for digital pathology image analysis
|Scientific Reports|2017|8.9k
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
|The Lancet|2020|2.6k
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2013|1.7k